EHD2: A Promising Drug Target / Biomarker (G30846)

Target Name: EHD2

NCBI ID: G30846

EHD2

EHD2: A Promising Drug Target / Biomarker

EHD2 (endothelial density-normalized hyperacetylase) is a protein that is expressed in endothelial cells, which are the cells that line the blood vessels. The function of EHD2 is not well understood, but it is known to be involved in the regulation of cell growth and differentiation. In recent years, researchers have become interested in using EHD2 as a drug target or biomarker for the treatment of various diseases, including cancer, heart disease, and diabetes.

Drug Target

EHD2 has been identified as a potential drug target due to its involvement in cell signaling pathways that are associated with various diseases. One of the key signaling pathways that EHD2 is involved in is the TGF-β pathway, which is a well-established regulator of cell growth and differentiation. The TGF-β pathway is involved in the development and maintenance of tissues, including blood vessels. EHD2 has been shown to play a role in the regulation of TGF-β signaling by activating the negative regulator, p21.

In addition to its involvement in the TGF-β pathway, EHD2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. EHD2 has been shown to be involved in the production of vascular endothelial growth factor (VEGF), which is a key factor in the regulation of angiogenesis.

Biomarker

EHD2 has also been identified as a potential biomarker for several diseases, including cancer, heart disease, and diabetes. One of the key reasons for its potential as a biomarker is its expression in a variety of tissues, including blood vessels, which makes it a potential indicator of disease.

In addition to its potential as a biomarker, EHD2 has also been shown to be involved in the regulation of cellular processes that are associated with the development and progression of diseases. For example, EHD2 has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together and form tissues.

Conclusion

In conclusion, EHD2 is a protein that is involved in several important cellular processes that are associated with the development and progression of diseases. Its potential as a drug target or biomarker makes it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of EHD2 in cell signaling pathways and its potential as a biomarker for diseases.

Protein Name: EH Domain Containing 2

Functions: ATP- and membrane-binding protein that controls membrane reorganization/tubulation upon ATP hydrolysis (By similarity). Plays a role in membrane trafficking between the plasma membrane and endosomes (PubMed:17233914). Important for the internalization of GLUT4. Required for fusion of myoblasts to skeletal muscle myotubes. Required for normal translocation of FER1L5 to the plasma membrane (By similarity). Regulates the equilibrium between cell surface-associated and cell surface-dissociated caveolae by constraining caveolae at the cell membrane (PubMed:25588833)

The "EHD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets